Hims & Hers Health (HIMS) Q1 Earnings Preview: What Investors Need to Know

Key Takeaways

• Hims & Hers Health delivers Q1 2026 financial results following Monday’s market close on May 11
• Wall Street forecasts revenue between $616M and $619M, representing merely 5.2% annual growth — a dramatic slowdown from the 111% expansion witnessed in Q1 2025
• The telehealth platform secured an agreement with Novo Nordisk in March, obtaining authorization to distribute branded Wegovy and Ozempic — however, sales commenced March 26, limiting first-quarter financial contribution
• Earnings per share projections land at 3–4 cents, reflecting an approximately 90% decline compared to last year’s results
• Shares have surged nearly 50% during the previous month despite substantial short interest exceeding 35% and a predominantly neutral analyst consensus from 17 Wall Street firms

Heading into Monday’s quarterly disclosure, Hims & Hers Health (HIMS) trades at $28.46, posting gains of roughly 32% across the last 30 days and climbing approximately 77% from its February 27 fifty-two-week bottom. Yet the telehealth stock remains underwater for 2026, declining more than 23% year-to-date.

Hims & Hers Health, Inc., HIMS

Analysts characterize this upcoming report as a “transitional quarter.” Revenue projections cluster around the $616M–$619M range, translating to merely 5.2% year-over-year advancement. This marks a significant deceleration from the exceptional 111% revenue expansion HIMS achieved during the comparable period last year.

The dominant narrative surrounding this earnings release centers on the company’s strategic transition from compounded GLP-1 weight-management medications to branded Novo Nordisk alternatives. Following Novo Nordisk’s withdrawal of its patent litigation on March 9, both organizations finalized an arrangement granting HIMS distribution rights for Wegovy and Ozempic via its digital healthcare platform.

Timing presents a complication, however. These branded pharmaceutical products became available through the platform starting March 26. Since the first quarter concluded March 31, meaningful revenue contribution will probably materialize in Q2 reporting instead.

Subscription Metrics Under Close Examination

Wall Street will scrutinize subscriber acquisition and retention metrics carefully. HIMS surpassed 2.5 million active subscribers approaching the conclusion of 2025 — representing 16% growth from the 2.2 million subscriber count recorded at 2024’s end, and substantially exceeding the 1.5 million subscribers from late 2023.

Customer retention carries equal importance. Approximately 82% of platform users continue their subscriptions past the three-month threshold, while roughly 90% of recurring revenues originate from the established customer cohort. Should HIMS demonstrate stable or expanding subscriber figures, it reinforces confidence in full-year financial projections.

Profitability expectations remain modest — consensus estimates place earnings per share at just 3 to 4 cents, marking roughly a 90% annual contraction. While this deterioration may already factor into current valuations, any downward surprise could intensify selling pressure in a security already experiencing significant short-seller activity.

Wall Street Maintains Reserved Outlook

Among the 17 analysts providing HIMS coverage, four assign Buy ratings, 12 recommend Hold positions, and one issues a Sell rating. The consensus twelve-month price objective stands at $31.86 — approximately 12% above Friday’s closing price of $28.46.

Short interest positioning remains substantially elevated above 35% of available float, equating to approximately 70 million shares held short. With a volatility beta of 2.43, this equity demonstrates pronounced price movements in either direction.

Institutional accumulation accelerated during Q1, with institutional selling activity 88% below buying volume — marking a significant reversal from the considerable institutional outflows observed throughout Q4 2025.

The Food and Drug Administration has additionally proposed eliminating semaglutide, tirzepatide, and liraglutide from its 503B bulks inventory, which would retrospectively validate HIMS’s strategic decision to abandon the compounded GLP-1 segment.

HIMS has fallen short of Wall Street’s revenue projections on multiple occasions throughout the previous twenty-four months. Financial results are scheduled for release following Monday’s trading session on May 11.

The post Hims & Hers Health (HIMS) Q1 Earnings Preview: What Investors Need to Know appeared first on Blockonomi.